Extension of Time to File SOU

SEKTAYOS

Intercept Pharmaceuticals, Inc.

Request for Extension of Time to File a Statement of Use

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005)
OMB No. 0651-0054 (Exp 12/31/2020)

Request for Extension of Time to File a Statement of Use
(15 U.S.C. Section 1051(d))


The table below presents the data as entered.

Input Field
Entered
SERIAL NUMBER 88398934
LAW OFFICE ASSIGNED LAW OFFICE 117
MARK SECTION
MARK SEKTAYOS (see, http://uspto.report/TM/88398934/mark.png)
STANDARD CHARACTERS YES
USPTO-GENERATED IMAGE YES
LITERAL ELEMENT SEKTAYOS
OWNER SECTION (current)
NAME Intercept Pharmaceuticals, Inc.
STREET 10 Hudson Yards, 37th Floor
CITY New York
STATE New York
ZIP/POSTAL CODE 10001
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY United States
OWNER SECTION (proposed)
NAME Intercept Pharmaceuticals, Inc.
STREET 10 Hudson Yards, 37th Floor
CITY New York
STATE New York
ZIP/POSTAL CODE 10001
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY United States
EMAIL XXXX
CORRESPONDENCE INFORMATION (current)
NAME Jeffrey H. Greene
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE trademarks@cooley.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) NOT PROVIDED
CORRESPONDENCE INFORMATION (proposed)
NAME Jeffrey H. Greene
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE trademarks@cooley.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) aanderson@cooley.com
GOODS AND/OR SERVICES SECTION
INTERNATIONAL CLASS 005
CURRENT IDENTIFICATION Pharmaceutical preparations, namely, therapeutic bile acid analogues; pharmaceutical preparations for the treatment of liver diseases, disorders and conditions; pharmaceuticals for treating nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, liver fibrosis, and liver cirrhosis
GOODS OR SERVICES KEEP ALL LISTED
EXTENSION SECTION
EXTENSION NUMBER 1
ALLOWANCE MAIL DATE 10/08/2019
STATEMENT OF USE NO
PAYMENT SECTION
NUMBER OF CLASSES 1
SUBTOTAL AMOUNT [EXTENSION FEE] 125
TOTAL AMOUNT 125
SIGNATURE SECTION
SIGNATURE /Peter Cicala/
SIGNATORY'S NAME Cicala, Peter
SIGNATORY'S POSITION Chief IP Counsel
DATE SIGNED 03/23/2020
SIGNATORY'S PHONE NUMBER 000-000-0000
FILING INFORMATION
SUBMIT DATE Tue Mar 24 05:33:09 ET 2020
TEAS STAMP USPTO/ESU-XX.XXX.XX.XXX-2
0200324053309733938-88398
934-7107ef3383ec2496789d8
887133a52b142667343ee3552
eab1196942d870ab3-DA-3309
9088-20200323071530908298



Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005)
OMB No. 0651-0054 (Exp 12/31/2020)


SOU Extension Request
(15 U.S.C. Section 1051(d))


To the Commissioner for Trademarks:

MARK: SEKTAYOS (see, http://uspto.report/TM/88398934/mark.png)
SERIAL NUMBER: 88398934

OWNER AND/OR ENTITY INFORMATION
The owner proposes to amend the following:
Current: Intercept Pharmaceuticals, Inc., having an address of
      10 Hudson Yards, 37th Floor
      New York, New York 10001
      United States
Proposed: Intercept Pharmaceuticals, Inc., having an address of BB
      10 Hudson Yards, 37th Floor
      New York, New York 10001
      United States
      Phone:
      Fax:
      Email: XXXX

The owner requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application.    The Notice of Allowance mailing date was 10/08/2019.

For International Class 005:
Current identification: Pharmaceutical preparations, namely, therapeutic bile acid analogues; pharmaceutical preparations for the treatment of liver diseases, disorders and conditions; pharmaceuticals for treating nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, liver fibrosis, and liver cirrhosis

For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this specific class.


This is the first extension request.

Correspondence Information (current):
      Jeffrey H. Greene
      PRIMARY EMAIL FOR CORRESPONDENCE: trademarks@cooley.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): NOT PROVIDED

Correspondence Information (proposed):
      Jeffrey H. Greene
      PRIMARY EMAIL FOR CORRESPONDENCE: trademarks@cooley.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): aanderson@cooley.com


Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the owner/holder and the owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).





A fee payment in the amount of $125 will be submitted with the form, representing payment for 1 class.


Declaration

STATEMENTS: The signatory believes that: the applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all the goods/services under Section 1(b) in the notice of allowance or as subsequently modified, or, if applicable, the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with all the goods/services/collective membership organization under Section 1(b) in the notice of allowance or as subsequently modified; and that to the best of the signatory's knowledge and belief, no other persons, except, if applicable, members and concurrent users, have the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services/collective membership organization of such other persons, to cause confusion or mistake, or to deceive.

DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any resulting registration, declares that all statements made of his/her own knowledge are true and that all statements made on information and belief are believed to be true.


Signature: /Peter Cicala/      Date Signed: 03/23/2020
Signatory's Name: Cicala, Peter
Signatory's Position: Chief IP Counsel
Signatory's Phone: 000-000-0000

RAM Sale Number: 88398934
RAM Accounting Date: 03/24/2020

Serial Number: 88398934
Internet Transmission Date: Tue Mar 24 05:33:09 ET 2020
TEAS Stamp: USPTO/ESU-XX.XXX.XX.XXX-2020032405330973
3938-88398934-7107ef3383ec2496789d888713
3a52b142667343ee3552eab1196942d870ab3-DA
-33099088-20200323071530908298




uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed